EA
SRNE

Eudaimonia Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Eudaimonia Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-138,887
Closed -$123K – 169
2022
Q4 		$123K Hold
138,887
– – 0.08% 147
2022
Q3 		$218K Buy
138,887
+7,700
+6% +$17.5K 0.15% 137
2022
Q2 		$264K Buy
131,187
+10,787
+9% +$18.7K 0.18% 124
2022
Q1 		$281K Hold
120,400
– – 0.16% 130
2021
Q4 		$560K Buy
+120,400
New +$747K 0.33% 86

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Eudaimonia Advisors's SRNE Position: Q1 2023 in Review

Eudaimonia Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 138,887 shares — an estimated $123K sold.

Eudaimonia Advisors first reported a position in SRNE in Q4 2021 and held it in 5 quarters. The position peaked at $560K in Q4 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Eudaimonia Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Eudaimonia Advisors sold 138,887 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $123K.
  • Eudaimonia Advisors first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 5 quarters.
  • Eudaimonia Advisors's Sorrento Therapeutics, Inc. position peaked at $560K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Eudaimonia Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.